Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04088630 · ClinicalTrials.gov registry record · Early Phase 1
Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage
A Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
NCT04088630 is a Early Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 28 participants.
The verdict
NCT04088630, a Early Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of a single dose of fingolimod in patients with primary spontaneous intracerebral hemorrhage (ICH).
Interventions
- DRUG Placebo
- DRUG Fingolimod
- DRUG Open-label Fingolimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-08-07 |
| Est. Completion | 2024-06-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04088630
The ClinicalTrials.gov registry entry for NCT04088630 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04088630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04088630 about?
NCT04088630 is a clinical study titled "Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage". The purpose of this study is to test the safety and effectiveness of a single dose of fingolimod in patients with primary spontaneous intracerebral hemorrhage (ICH).
What is the current status of trial NCT04088630?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2020-08-07. Estimated completion is 2024-06-05.
What interventions are being tested in trial NCT04088630?
The interventions under investigation include: Placebo (DRUG), Fingolimod (DRUG), Open-label Fingolimod (DRUG).
Who is sponsoring clinical trial NCT04088630?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.